**1.2 TA immunosuppression in KT**

PEX and IA can remove the already produced antibodies, but they cannot influence the antibody production. However, after TA a rise in antibody formation and increase in B-cell proliferation occurs [8]. Therefore, TA should be coupled with adequate immunosuppression. In TA prior to or after renal transplantation the most widely used immunosuppressive medications are the biological agents— Thymoglobulin (ATG, dose 1–1.5 mg/kg, different protocols exist), Rituximab (standard dose 375 mg/m2 /weekly for 2–4 weeks) and intravenous immunoglobulins (IVIG, 100 mg/kg after each procedure). Eculizumab is also taken into consideration in high-risk patients prior to and after KT. Its effectivity is fully recognized in posttransplant atypical hemolytic uremic syndrome (aHUS). Further trials are needed to evaluate the exact place of this monoclonal drug in transplantation [9]. In addition, as the KT in sensitized patients is regarded as high-risk procedure, anti-CD25 agents can also be applied.
